A Phase II/III Trial of Oral Azacitidine (Oral-AZA) in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes (MDS)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
Key words
MDS, myelodysplastic syndrome, oral azacitidine, clinical trial, myeloid malignancies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined